RegeneRx (RGN) Working with U.S. Military to Test Tβ4 Against Exposure to Chemical Agents in the Eye
More News related to RGN
- REGENERX (RGN) Reports Study Data on Tb4 Drug Candidates
- Unusual 11 Mid-Day Movers 9/30: HOKU, ICCC, VSR, DSCO Higher; CIT, RGN, ICON, HX Lower
- Morning Movers 9/30: HOKU, ICCC, VSR, CFW, DSCO Higher; CIT, HX, RGN, ICON, APAB, RMTI Lower
- Regenerx Biopharma (RGN) Slumps as $4.7M Offering Announced
- Regenerx (RGN) Said Tb4 Significantly Improves Functional Recovery in MS Animal Model
More News related to Corporate News
- CAS Medical (CASM) Announces Publication of Two FORE-SIGHT Studies
- GE (GE) Transportation Unit to Deliver 10 AC 44i Locomotives to ALL
- AK Steel (AKS) Tacks on $155/Ton Surcharge for Electrical Steel Products Shipped in 2010
- Builders FirstSource (BLDR) Updates on Recent Recapitalization Transactions
- Cree (CREE) Acquires SiC Patent Portfolio from Daimler AG
REGENERX BIOPHARMACEUTICALS, INC. (NYSE: RGN) announced that it is collaborating with the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and Dr. Gabriel Sosne, Associate Professor of Ophthalmology at Wayne State University, to evaluate Tβ4's (RGN-259 eye drops) ability to prevent or reduce damage to the eye caused by exposure to chemical agents. The ability to prevent or reduce such damage is the focus of substantial efforts by both the military and homeland security. The project will consist of a series of research experiments over the next twelve months with Tβ4, which is being commercially developed by RegeneRx and is in Phase II clinical trials.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
